Multicenter phase II trial of 90Y-Ibritumomab tiuxetan with high-dose chemotherapy (busulfan/cyclophosphamide/etoposide) followed by autologous stem cell transplantation in relapsed, refractoried, or high-risk B-cell NHL

被引：0
|
作者：
Kang, Byung Woog [1 ]
Jo, Jae-Cheol [1 ]
Kim, Shin [1 ]
Jang, Geundoo [1 ]
Lee, Sung Sook [1 ]
Sym, Sun Jin [1 ]
Ryu, Jin-Sook [1 ]
Kim, Won Seog [2 ]
Yoon, Sung Soo [3 ]
Suh, Cheolwon [1 ]
机构：
[1] Univ Ulsan, Coll Med, Seoul, South Korea
[2] Sungkyunkwan Univ, Sch Med, Seoul, South Korea
[3] Seoul Natl Univ, Coll Med, Seoul, South Korea
来源：
BLOOD | 2007年 / 110卷 / 11期
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
1914
引用
收藏
页码：569A / 569A
页数：1
相关论文
共 50 条
  • [1] Multicentre phase II trial of 90Y-ibritumomab tiuxetan with high-dose chemotherapy (busulfan/cyclophosphamide/etoposide) followed by autologous stem cell transplantation in relapsed, refractory, or high-risk B-cell NHL
    Kang, B. W.
    Kim, S.
    Cho, Y. H.
    Ryu, J. -S.
    Kim, W. S.
    Yoon, S. S.
    Suh, C.
    BONE MARROW TRANSPLANTATION, 2008, 41 : S248 - S248
  • [2] Multicenter phase II clinical trial of 90y-ibritumomab tiuxetan with high-dose chemotherapy followed by autologous stem cell transplantation in relapsed, refractory, or high-risk B-cell non-Hodgkins lymphoma, preliminary report
    Kang, B. W.
    Jo, J. C.
    Ryu, J. S.
    Kim, S.
    Cho, Y. H.
    Kim, W. S.
    Yoon, S. S.
    Suh, C.
    HAEMATOLOGICA-THE HEMATOLOGY JOURNAL, 2007, 92 : 268 - 268
  • [3] Phase I trial of 90Y-ibritumomab tiuxetan in patients with relapsed B-cell non-Hodgkin's lymphoma following high-dose chemotherapy and autologous stem cell transplantation
    Vose, Julie M.
    Bierman, Philip J.
    Loberiza, Fausto R., Jr.
    Bociek, Robert G.
    Matso, Daniel
    Armitage, James O.
    LEUKEMIA & LYMPHOMA, 2007, 48 (04) : 683 - 690
  • [4] A phase 1/2 trial of high-dose yttrium-90-ibritumomab tiuxetan in combination with high-dose etoposide and cyclophosphamide followed by autologous stem cell transplantation in patients with poor-risk or relapsed non-Hodgkin lymphoma
    Nademanee, A
    Forman, S
    Molina, A
    Fung, H
    Smith, D
    Dagis, A
    Kwok, C
    Yamauchi, D
    Anderson, AL
    Falk, P
    Krishnan, A
    Kirschbaum, M
    Kogut, N
    Nakamura, R
    O'Donnell, M
    Parker, P
    Popplewell, L
    Pullarkat, V
    Rodriguez, R
    Sahebi, F
    Smith, E
    Snyder, D
    Stein, A
    Spielberger, R
    Zain, J
    White, C
    Raubitschek, A
    BLOOD, 2005, 106 (08) : 2896 - 2902
  • [5] Phase I clinical trial of Zevalin (90Y-ibritumomab) in patients with B-cell non-Hodgkin's lymphoma (NHL) with relapsed disease following high-dose chemotherapy and autologous stem cell transplantation (ASCT).
    Vose, JM
    Bierman, PJ
    Lynch, JC
    Bociek, GR
    Multani, PS
    Armitage, JO
    BLOOD, 2003, 102 (11) : 30A - 30A
  • [6] High-dose radioimmunotherapy with yttrium 90 (90Y) ibritumomab tiuxetan with high-dose etoposide (VP-16) and cyclophosphamide (CY) followed by autologous hematopoietic cell transplant (AHCT) for poor-risk or relapsed B-cell non-Hodgkin's lymphoma (NHL):: Update of a phase I/II trial.
    Nademanee, A
    Forman, SJ
    Molina, A
    Kogut, N
    Fung, HC
    Yamauchi, D
    Anderson, AL
    Smith, D
    Liu, AN
    Raubitschek, A
    JOURNAL OF CLINICAL ONCOLOGY, 2004, 22 (14) : 559S - 559S
  • [7] Yttrium-90-ibritumomab tiuxetan in combination with intravenous busulfan, cyclophosphamide, and etoposide followed by autologous stem cell transplantation in patients with relapsed or refractory B-cell non-Hodgkin’s lymphoma
    Byung Woog Kang
    Won Seog Kim
    Chul Kim
    Geundoo Jang
    Sung Sook Lee
    Yoon Hee Choi
    Dae Ho Lee
    Sang We Kim
    Shin Kim
    Jin-Sook Ryu
    Jooryung Huh
    Jung Shin Lee
    Cheolwon Suh
    Investigational New Drugs, 2010, 28 : 516 - 522
  • [8] Yttrium-90-ibritumomab tiuxetan in combination with intravenous busulfan, cyclophosphamide, and etoposide followed by autologous stem cell transplantation in patients with relapsed or refractory B-cell non-Hodgkin's lymphoma
    Kang, Byung Woog
    Kim, Won Seog
    Kim, Chul
    Jang, Geundoo
    Lee, Sung Sook
    Choi, Yoon Hee
    Lee, Dae Ho
    Kim, Sang We
    Kim, Shin
    Ryu, Jin-Sook
    Huh, Jooryung
    Lee, Jung Shin
    Suh, Cheolwon
    INVESTIGATIONAL NEW DRUGS, 2010, 28 (04) : 516 - 522
  • [9] PHASE II PILOT STUDY OF TANDEM CONSOLIDATION USING 90Y-IBRITUMOMAB TIUXETAN (ZEVALIN) AND HIGH-DOSE THERAPY WITH AUTOLOGOUS PERIPHERAL BLOOD STEM CELL TRANSPLANTATION IN HIGH-RISK PATIENTS IN PRIMARY REMISSION WITH DIFFUSE LARGE B-CELL LYMPHOMA
    Cho, S. G.
    Kim, J. H.
    Cho, B. S.
    Eom, K. S.
    Kim, Y. J.
    Kim, H. J.
    Lee, S.
    Min, C. K.
    Lee, J. W.
    Min, W. S.
    Kim, C. C.
    HAEMATOLOGICA-THE HEMATOLOGY JOURNAL, 2009, 94 : 650 - 650
  • [10] High dose Y-90-Ibritumomab-Tiuxetan with autologous stem cell transplantation in refractory-resistant NHL patients
    Grana, Chiara
    Baio, Silvia
    Bodei, Lisa
    Papi, Stefano
    Vanazzi, Anna
    Cremonesi, Marta
    Chinol, Marco
    Martinelli, Giovanni
    Paganelli, Giovanni
    JOURNAL OF NUCLEAR MEDICINE, 2010, 51
12345